SYNTARA LIMITED - Announcements

7.41%

2.9¢

Market Cap $47.20M

Healthcare Biotechnology

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

SNT	Change in substantial holding		14/08/23	647.58KB	Share
SNT	Application for quotation of securities - PXS		08/08/23	24.91KB	Share
SNT	Notification of cessation of securities - PXS		08/08/23	21.51KB	Share
SNT	PXS to Receive Prepayment of 2023 Research Tax Incentive	PRICE SENSITIVE	08/08/23	188.43KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/07/23	643.63KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	330.79KB	Share
SNT	Pharmaxis Quarterly Shareholder Update and Investor Briefing		28/07/23	203.69KB	Share
SNT	Ceasing to be a substantial holder		26/07/23	85.16KB	Share
SNT	Investor Presentation		20/07/23	2.74MB	Share
SNT	PXS to Present at MST Access Biotech Hidden Gems Forum		18/07/23	187.17KB	Share
SNT	Investor Presentation MF 101 Interim Data		12/07/23	626.32KB	Share
SNT	Final Set of Interim Data from PXS-5505 in Myelofibrosis	PRICE SENSITIVE	12/07/23	245.37KB	Share
SNT	Application for quotation of securities - PXS		05/07/23	24.9KB	Share
SNT	Notification of cessation of securities - PXS		05/07/23	21.51KB	Share
SNT	Change in substantial holding		05/07/23	585.34KB	Share
SNT	Investor presentation		24/05/23	1.37MB	Share
SNT	PXS Announces Encouraging Results from Phase 1c Scar Study	PRICE SENSITIVE	23/05/23	235.37KB	Share
SNT	Trading Halt	PRICE SENSITIVE	22/05/23	369.47KB	Share
SNT	Investor Presentation - Quarterly Briefing		28/04/23	1.02MB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	625.51KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	323.77KB	Share
SNT	PXS Quarterly Update and Investor Briefing		21/04/23	203.05KB	Share
SNT	After FDA Review PXS Accelerates Plans for Combination Study	PRICE SENSITIVE	12/04/23	223.25KB	Share
SNT	Ceasing to be a substantial holder		31/03/23	96.21KB	Share
SNT	Pharmaxis Drug Study Published in Nature Communications		23/03/23	215.64KB	Share
SNT	Becoming a substantial holder		22/03/23	114.34KB	Share
SNT	Change in substantial holding		21/03/23	88.92KB	Share
SNT	Application for quotation of securities - PXS		20/03/23	24.95KB	Share
SNT	Application for quotation of securities - PXS		16/03/23	25.35KB	Share
SNT	Change in substantial holding		13/02/23	623.85KB	Share
SNT	PXS Securities Trading Policy - Updated 10 Feb 2023		13/02/23	226.79KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	10/02/23	718.73KB	Share
SNT	Investor Presentation		06/02/23	2.7MB	Share
SNT	Investor Presentation		31/01/23	571.67KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/01/23	529.73KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	219.35KB	Share
SNT	Quarterly Shareholder Update and Investor Briefing		23/01/23	128.55KB	Share
SNT	Application for quotation of securities - PXS		23/01/23	24.94KB	Share
SNT	Initial Director's Interest Notice		16/01/23	136.62KB	Share
SNT	Director Appointment/Resignation		16/01/23	107.75KB	Share
SNT	Pharmaxis Receives $5m R&D Tax Incentive		09/01/23	86.6KB	Share
SNT	Application for quotation of securities - PXS		22/12/22	24.94KB	Share
SNT	Pharmaxis Skin Scarring Study Fully Recruited		21/12/22	171.86KB	Share
SNT	Initial Director's Interest Notice		14/12/22	134.47KB	Share
SNT	Pharmaxis Appoints Dr Simon Green as Director		14/12/22	108.42KB	Share
SNT	Change in substantial holding		14/12/22	202.71KB	Share
SNT	PXS Drug Profiled American Society of Hematology Conference		12/12/22	203.31KB	Share
SNT	Application for quotation of securities - PXS		12/12/22	24.94KB	Share
SNT	Change in substantial holding		08/12/22	161.16KB	Share
SNT	Becoming a substantial holder		07/12/22	618.16KB	Share
SNT	Change in substantial holding		06/12/22	173.11KB	Share
SNT	Section 708(5)(e) Notice		05/12/22	140.88KB	Share
SNT	Ceasing to be a substantial holder		02/12/22	615.92KB	Share
SNT	Change of Director's Interest Notice		02/12/22	140.49KB	Share
SNT	Change of Director's Interest Notice		02/12/22	143.55KB	Share
SNT	Change of Director's Interest Notice		02/12/22	145.38KB	Share
SNT	Notification regarding unquoted securities - PXS		02/12/22	28.3KB	Share
SNT	Application for quotation of securities - PXS		02/12/22	23.16KB	Share
SNT	Change of Director's Interest Notice		29/11/22	139.34KB	Share
SNT	Notification regarding unquoted securities - PXS		29/11/22	25.39KB	Share
SNT	Results of Meeting		29/11/22	212.72KB	Share
SNT	Chairman's Address to Shareholders		29/11/22	175.76KB	Share
SNT	CEO Presentation to 2022 AGM		29/11/22	2.1MB	Share
SNT	Application for quotation of securities - PXS		23/11/22	24.91KB	Share
SNT	Investor Presentation		09/11/22	1.78MB	Share
SNT	Application for quotation of securities - PXS		07/11/22	25.31KB	Share
SNT	Change of Director's Interest Notice		01/11/22	145.21KB	Share
SNT	Application for quotation of securities - PXS		01/11/22	27.02KB	Share
SNT	Change of Director's Interest Notice		01/11/22	142.2KB	Share
SNT	Application for quotation of securities - PXS		01/11/22	25.47KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/10/22	869.62KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	219.1KB	Share
SNT	Becoming a substantial holder		28/10/22	87.05KB	Share
SNT	Corporate Governance Statement		28/10/22	189.65KB	Share
SNT	Appendix 4G		28/10/22	186.18KB	Share
SNT	Annual Report to shareholders		28/10/22	1.24MB	Share
SNT	Notice of Annual General Meeting/Proxy Form		28/10/22	420.6KB	Share
SNT	Change in substantial holding		28/10/22	185.65KB	Share
SNT	Becoming a substantial holder		27/10/22	253.44KB	Share
SNT	Section 708A(5)(e) Notice		26/10/22	140.87KB	Share
SNT	Application for quotation of securities - PXS		26/10/22	24.57KB	Share
SNT	Proposed issue of securities - PXS		19/10/22	25.38KB	Share
SNT	Proposed issue of securities - PXS		19/10/22	25.12KB	Share
SNT	PXS announces positive interim data from myelofibrosis trial	PRICE SENSITIVE	19/10/22	257.53KB	Share
SNT	Investor Presentation	PRICE SENSITIVE	19/10/22	1.56MB	Share
SNT	Placement	PRICE SENSITIVE	19/10/22	223.88KB	Share
SNT	Trading Halt	PRICE SENSITIVE	18/10/22	372.8KB	Share
SNT	Proposed Issue of Securities to Chief Executive Officer		18/10/22	159.29KB	Share
SNT	Notification regarding unquoted securities - PXS		18/10/22	26.59KB	Share
SNT	Investor Presentation Interim Data from Skin Scarring Study		26/09/22	1MB	Share
SNT	PXS Releases Promising Interim Data from Skin Scarring Study	PRICE SENSITIVE	26/09/22	182.78KB	Share
SNT	Date of Virtual AGM and Date for Director Nominations		13/09/22	178.58KB	Share
SNT	Investor presentation		06/09/22	1.05MB	Share
SNT	Application for quotation of securities - PXS		01/09/22	24.91KB	Share
SNT	PXS to Receive Stg2.9m from Parkinsons UK for New Trial	PRICE SENSITIVE	01/09/22	208.6KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	30/08/22	859.7KB	Share
SNT	Change of Director's Interest Notice		23/08/22	144.17KB	Share
SNT	Notification of cessation of securities - PXS		23/08/22	21.68KB	Share
SNT	Notification of cessation of securities - PXS		22/08/22	21.51KB	Share
SNT	Pharmaxis Receives Aptar Option Exercise Fees of US$5m		16/08/22	108.87KB	Share

SNT Change in substantial holding
14/08/23		647.58KB	Share
SNT Application for quotation of securities - PXS
08/08/23		24.91KB	Share
SNT Notification of cessation of securities - PXS
08/08/23		21.51KB	Share
SNT PXS to Receive Prepayment of 2023 Research Tax Incentive
08/08/23	PRICE SENSITIVE	188.43KB	Share
SNT Quarterly Activities Report
31/07/23	PRICE SENSITIVE	643.63KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	330.79KB	Share
SNT Pharmaxis Quarterly Shareholder Update and Investor Briefing
28/07/23		203.69KB	Share
SNT Ceasing to be a substantial holder
26/07/23		85.16KB	Share
SNT Investor Presentation
20/07/23		2.74MB	Share
SNT PXS to Present at MST Access Biotech Hidden Gems Forum
18/07/23		187.17KB	Share
SNT Investor Presentation MF 101 Interim Data
12/07/23		626.32KB	Share
SNT Final Set of Interim Data from PXS-5505 in Myelofibrosis
12/07/23	PRICE SENSITIVE	245.37KB	Share
SNT Application for quotation of securities - PXS
05/07/23		24.9KB	Share
SNT Notification of cessation of securities - PXS
05/07/23		21.51KB	Share
SNT Change in substantial holding
05/07/23		585.34KB	Share
SNT Investor presentation
24/05/23		1.37MB	Share
SNT PXS Announces Encouraging Results from Phase 1c Scar Study
23/05/23	PRICE SENSITIVE	235.37KB	Share
SNT Trading Halt
22/05/23	PRICE SENSITIVE	369.47KB	Share
SNT Investor Presentation - Quarterly Briefing
28/04/23		1.02MB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	625.51KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	323.77KB	Share
SNT PXS Quarterly Update and Investor Briefing
21/04/23		203.05KB	Share
SNT After FDA Review PXS Accelerates Plans for Combination Study
12/04/23	PRICE SENSITIVE	223.25KB	Share
SNT Ceasing to be a substantial holder
31/03/23		96.21KB	Share
SNT Pharmaxis Drug Study Published in Nature Communications
23/03/23		215.64KB	Share
SNT Becoming a substantial holder
22/03/23		114.34KB	Share
SNT Change in substantial holding
21/03/23		88.92KB	Share
SNT Application for quotation of securities - PXS
20/03/23		24.95KB	Share
SNT Application for quotation of securities - PXS
16/03/23		25.35KB	Share
SNT Change in substantial holding
13/02/23		623.85KB	Share
SNT PXS Securities Trading Policy - Updated 10 Feb 2023
13/02/23		226.79KB	Share
SNT Half Yearly Report and Accounts
10/02/23	PRICE SENSITIVE	718.73KB	Share
SNT Investor Presentation
06/02/23		2.7MB	Share
SNT Investor Presentation
31/01/23		571.67KB	Share
SNT Quarterly Activities Report
31/01/23	PRICE SENSITIVE	529.73KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	219.35KB	Share
SNT Quarterly Shareholder Update and Investor Briefing
23/01/23		128.55KB	Share
SNT Application for quotation of securities - PXS
23/01/23		24.94KB	Share
SNT Initial Director's Interest Notice
16/01/23		136.62KB	Share
SNT Director Appointment/Resignation
16/01/23		107.75KB	Share
SNT Pharmaxis Receives $5m R&D Tax Incentive
09/01/23		86.6KB	Share
SNT Application for quotation of securities - PXS
22/12/22		24.94KB	Share
SNT Pharmaxis Skin Scarring Study Fully Recruited
21/12/22		171.86KB	Share
SNT Initial Director's Interest Notice
14/12/22		134.47KB	Share
SNT Pharmaxis Appoints Dr Simon Green as Director
14/12/22		108.42KB	Share
SNT Change in substantial holding
14/12/22		202.71KB	Share
SNT PXS Drug Profiled American Society of Hematology Conference
12/12/22		203.31KB	Share
SNT Application for quotation of securities - PXS
12/12/22		24.94KB	Share
SNT Change in substantial holding
08/12/22		161.16KB	Share
SNT Becoming a substantial holder
07/12/22		618.16KB	Share
SNT Change in substantial holding
06/12/22		173.11KB	Share
SNT Section 708(5)(e) Notice
05/12/22		140.88KB	Share
SNT Ceasing to be a substantial holder
02/12/22		615.92KB	Share
SNT Change of Director's Interest Notice
02/12/22		140.49KB	Share
SNT Change of Director's Interest Notice
02/12/22		143.55KB	Share
SNT Change of Director's Interest Notice
02/12/22		145.38KB	Share
SNT Notification regarding unquoted securities - PXS
02/12/22		28.3KB	Share
SNT Application for quotation of securities - PXS
02/12/22		23.16KB	Share
SNT Change of Director's Interest Notice
29/11/22		139.34KB	Share
SNT Notification regarding unquoted securities - PXS
29/11/22		25.39KB	Share
SNT Results of Meeting
29/11/22		212.72KB	Share
SNT Chairman's Address to Shareholders
29/11/22		175.76KB	Share
SNT CEO Presentation to 2022 AGM
29/11/22		2.1MB	Share
SNT Application for quotation of securities - PXS
23/11/22		24.91KB	Share
SNT Investor Presentation
09/11/22		1.78MB	Share
SNT Application for quotation of securities - PXS
07/11/22		25.31KB	Share
SNT Change of Director's Interest Notice
01/11/22		145.21KB	Share
SNT Application for quotation of securities - PXS
01/11/22		27.02KB	Share
SNT Change of Director's Interest Notice
01/11/22		142.2KB	Share
SNT Application for quotation of securities - PXS
01/11/22		25.47KB	Share
SNT Quarterly Activities Report
31/10/22	PRICE SENSITIVE	869.62KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	219.1KB	Share
SNT Becoming a substantial holder
28/10/22		87.05KB	Share
SNT Corporate Governance Statement
28/10/22		189.65KB	Share
SNT Appendix 4G
28/10/22		186.18KB	Share
SNT Annual Report to shareholders
28/10/22		1.24MB	Share
SNT Notice of Annual General Meeting/Proxy Form
28/10/22		420.6KB	Share
SNT Change in substantial holding
28/10/22		185.65KB	Share
SNT Becoming a substantial holder
27/10/22		253.44KB	Share
SNT Section 708A(5)(e) Notice
26/10/22		140.87KB	Share
SNT Application for quotation of securities - PXS
26/10/22		24.57KB	Share
SNT Proposed issue of securities - PXS
19/10/22		25.38KB	Share
SNT Proposed issue of securities - PXS
19/10/22		25.12KB	Share
SNT PXS announces positive interim data from myelofibrosis trial
19/10/22	PRICE SENSITIVE	257.53KB	Share
SNT Investor Presentation
19/10/22	PRICE SENSITIVE	1.56MB	Share
SNT Placement
19/10/22	PRICE SENSITIVE	223.88KB	Share
SNT Trading Halt
18/10/22	PRICE SENSITIVE	372.8KB	Share
SNT Proposed Issue of Securities to Chief Executive Officer
18/10/22		159.29KB	Share
SNT Notification regarding unquoted securities - PXS
18/10/22		26.59KB	Share
SNT Investor Presentation Interim Data from Skin Scarring Study
26/09/22		1MB	Share
SNT PXS Releases Promising Interim Data from Skin Scarring Study
26/09/22	PRICE SENSITIVE	182.78KB	Share
SNT Date of Virtual AGM and Date for Director Nominations
13/09/22		178.58KB	Share
SNT Investor presentation
06/09/22		1.05MB	Share
SNT Application for quotation of securities - PXS
01/09/22		24.91KB	Share
SNT PXS to Receive Stg2.9m from Parkinsons UK for New Trial
01/09/22	PRICE SENSITIVE	208.6KB	Share
SNT Preliminary Final Report
30/08/22	PRICE SENSITIVE	859.7KB	Share
SNT Change of Director's Interest Notice
23/08/22		144.17KB	Share
SNT Notification of cessation of securities - PXS
23/08/22		21.68KB	Share
SNT Notification of cessation of securities - PXS
22/08/22		21.51KB	Share
SNT Pharmaxis Receives Aptar Option Exercise Fees of US$5m
16/08/22		108.87KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 2.9¢		Change 0.002(7.41%)		Mkt cap ! $47.20M

Open	High	Low	Value	Volume
2.8¢	3.0¢	2.7¢	$521.0K	18.11M

Buyers (Bids)

No.	Vol.	Price($)
6	1912467	2.9¢

Sellers (Offers)

Price($)	Vol.	No.
3.0¢	2634294	8

View Market Depth

No.	Vol.	Price($)
6	1912467	0.029
19	3752470	0.028
42	5774218	0.027
20	1048729	0.026
22	3565164	0.025

Price($)	Vol.	No.
0.030	2634294	8
0.031	1635714	8
0.032	1344200	7
0.033	700000	4
0.034	272824	2

Last trade - 16.10pm 12/08/2025 (20 minute delay)

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories